Blute M L, Amling C L, Bryant S C, Zincke H
Department of Urology, Mayo Clinic, Rochester, Minn. 55905, USA.
Mayo Clin Proc. 2000 Oct;75(10):1020-6. doi: 10.4065/75.10.1020.
To gain information regarding long-term follow-up in patients with synchronous bilateral solid renal neoplasms in whom renal-preserving surgery is imperative.
We examined our surgical experience and the survival outcome, as evaluated by Kaplan-Meier and log-rank analysis, of 94 patients (64 men and 30 women) who presented to the Mayo Clinic in Rochester, Minn, from 1973 to 1998 with bilateral synchronous solid renal neoplasms in the absence of von Hippel-Lindau disease. Follow-up of these patients ranged from 1 to 25 years, with a mean of 5.86 years and a median of 4.18 years. Tumors were staged according to the TNM classification. Pathologic staging and grading were usually performed on the kidney with the most extensive cancer. The Cox proportional hazards model was used to assess the relationship of grade (1-4), tumor size, and enucleation as opposed to extended (1 cm) partial nephrectomy on overall, cancer-specific, local recurrence-free, and metastasis-free survival.
Seventy-one patients (76%) had bilateral synchronous renal cell carcinoma, and 14 patients (15%) had a unilateral renal cell carcinoma with a contralateral benign solid neoplasm. Nine patients (10%) had bilateral benign solid lesions. Sixty-six patients (70%) underwent a single procedure, whereas 28 (30%) underwent staged surgical procedures. Fifty-one patients (54%) are alive, and 43 (46%) have died. Twenty patients (21%) died of metastatic disease, and 5 (5%) had a local recurrence. Cancer-specific survival of the 85 patients with at least 1 renal cell carcinoma still under observation was 81% (+/- 4.9% SE) and 59% (+/- 8.1% SE) at 5 and 10 years, respectively, and survival to local recurrence was 96% (+/- 2.6% SE) at 5 years and 93% (+/- 3.7% SE) at 10 years with 14 patients still under observation. Grade 3 was a statistically significant factor for metastasis (P < .001). A significant difference in metastasis-free survival and cancer-specific survival was noted dependent on pathologic T stage (P < .001 and P = .02, respectively), with patients with local pT3 disease having a higher rate of metastasis and cancer-specific death. Multivariate analysis revealed that tumor grade was associated with metastasis-free survival (P = .002) and tumor size with cancer-specific survival (P = .04). There was no statistical significance on survival outcome end points according to procedure performed, i.e., enucleation vs extended partial nephrectomy.
Long-term results of renal-preserving procedures for a series of patients with bilateral solid renal neoplasms indicate that grade, stage, and tumor size are significant predictors of outcome. Mean follow-up of over 5 years supports nephron-sparing techniques in selected patients because local recurrence was infrequent compared with distant metastasis.
获取有关双侧实性肾肿瘤患者长期随访的信息,对于这些患者而言,保留肾手术至关重要。
我们研究了1973年至1998年在明尼苏达州罗切斯特市梅奥诊所就诊的94例(64例男性和30例女性)双侧同步实性肾肿瘤且无冯·希佩尔-林道病患者的手术经验及生存结果,采用Kaplan-Meier法和对数秩检验进行评估。这些患者的随访时间为1至25年,平均5.86年,中位数为4.18年。肿瘤根据TNM分类进行分期。病理分期和分级通常在癌症范围最广的肾脏上进行。采用Cox比例风险模型评估肿瘤分级(1 - 4级)、肿瘤大小以及与扩大(1 cm)部分肾切除术相对的剜除术对总体生存、癌症特异性生存、无局部复发生存和无转移生存的影响。
71例(76%)患者为双侧同步肾细胞癌,14例(15%)为单侧肾细胞癌合并对侧良性实性肿瘤。9例(10%)为双侧良性实性病变。66例(70%)患者接受了单次手术,28例(30%)接受了分期手术。51例(54%)患者存活,43例(46%)患者死亡。20例(21%)死于转移性疾病,5例(5%)出现局部复发。仍在观察的85例至少有1例肾细胞癌患者的癌症特异性生存率在5年和10年时分别为81%(±4.9%标准误)和59%(±8.1%标准误),无局部复发生存率在5年时为96%(±2.6%标准误),10年时为93%(±3.7%标准误),仍有14例患者在观察中。3级是转移的统计学显著因素(P < 0.001)。根据病理T分期,无转移生存和癌症特异性生存存在显著差异(分别为P < 0.001和P = 0.02),局部pT3期患者的转移率和癌症特异性死亡率更高。多因素分析显示,肿瘤分级与无转移生存相关(P = 0.002),肿瘤大小与癌症特异性生存相关(P = 0.04)。根据所施行的手术方式,即剜除术与扩大部分肾切除术,生存结局终点无统计学差异。
一系列双侧实性肾肿瘤患者保留肾手术的长期结果表明,分级、分期和肿瘤大小是结局的重要预测因素。超过5年的平均随访支持在选定患者中采用保留肾单位技术,因为与远处转移相比,局部复发并不常见。